- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00445653
Risk Factors for Barrett's Esophagus in Patients With BE, Gastroesophageal Reflux, or Gastrointestinal Bleeding
Molecular Epidemiology of Barrett's Esophagus
RATIONALE: A study that evaluates DNA changes and other disease-related health information in patients with Barrett's esophagus, gastroesophageal reflux, or gastrointestinal bleeding may help doctors learn more about the risk factors for Barrett's esophagus.
PURPOSE: This clinical trial is looking at DNA changes and other disease-related health information as risk factors for Barrett's esophagus in patients with Barrett's esophagus, gastroesophageal reflux, or gastrointestinal bleeding.
Study Overview
Status
Conditions
Detailed Description
OBJECTIVES:
- Assess the role of several genetically determined factors that, in combination with CagA status, cigarette smoking, alcohol, and diet to varying degrees, result in an increased risk for Barrett's esophagus.
OUTLINE: This is a controlled study.
Patients complete questionnaires about demographics, medical history, smoking and alcohol history, current medications, frequency and chronicity of gastroesophageal reflux symptoms, and diet history.
Blood and tissue are collected and analyzed by DNA-based assays and enzyme-linked immunosorbent assay for CagA status and polymorphisms in detoxifying enzyme systems, other xenobiotic metabolism pathways (e.g., CYP1A1, CYP2E1, CYP3A4, CYP3A5, NQO, NAT-2), inflammatory gene pathways (e.g., IGF, IGFBF3), and in DNA repair genes or p53 pathways (e.g., XRCC1, p53 gene).
PROJECTED ACCRUAL: A total of 350 patients will be accrued for this study.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hospital Cancer Center
-
Boston, Massachusetts, United States, 02115
- Harvard School of Public Health
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
DISEASE CHARACTERISTICS:
Undergoing elective esophagogastroduodenoscopy for any of the following reasons:
- Surveillance of Barrett's esophagus
- Evaluation of severe or refractory gastroesophageal reflux disease or chest pain thought to be due to reflux
- Gastrointestinal bleeding
PATIENT CHARACTERISTICS:
- Not pregnant
PRIOR CONCURRENT THERAPY:
- Not specified
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Polymorphisms in detoxifying enzyme systems such as glutathione S-transferases (e.g., mu, theta, pi)
Time Frame: 2000-2013
|
2000-2013
|
Polymorphisms in other xenobiotic metabolism pathways (e.g., CYP1A1, CYP2E1, CYP3A4/5, NQO1, mEH, NAT-2)
Time Frame: 2000-2013
|
2000-2013
|
Polymorphisms in inflammatory gene pathways (e.g., MPO, MnSOD, IGF, IGFBF3, Il1-beta)
Time Frame: 2000-2013
|
2000-2013
|
Polymorphisms in DNA repair genes or the p53 pathways (e.g., ERCC2, XRCC1, p53, p73, CCND1, p21)
Time Frame: 2000-2013
|
2000-2013
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: David C. Christiani, MD, Massachusetts General Hospital
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CDR0000450146
- MGH-1999-P-010929/13 (Other Identifier: Partners Healthcare IRB)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Precancerous Condition
-
Xiyuan Hospital of China Academy of Chinese Medical...Guangdong Provincial Hospital of Traditional Chinese Medicine; Beijing Friendship... and other collaboratorsRecruiting
-
National Cancer Institute (NCI)TerminatedMetaplasia | Dysplasia | Pulmonary Precancerous ConditionUnited States
-
National Cancer Institute (NCI)CompletedNeoplasms | Precancerous ConditionsUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)Completed
-
Emory UniversityNational Institutes of Health (NIH)CompletedPrecancerous ConditionsUnited States
-
Renmin Hospital of Wuhan UniversityCompleted
-
All India Institute of Medical Sciences, New DelhiCompletedPrecancerous ConditionsIndia
-
City of Hope Medical CenterNational Cancer Institute (NCI)Completed
-
Northwestern UniversityNational Cancer Institute (NCI)CompletedPrecancerous ConditionUnited States